Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Quantum BioPharma Ltd. before investing.

In this article, we go over a few key elements for understanding Quantum BioPharma Ltd.’s stock price such as:

• Quantum BioPharma Ltd.’s current stock price and volume
• Why Quantum BioPharma Ltd.’s stock price changed recently
• Upgrades and downgrades for QNTM from analysts
• QNTM’s stock price momentum as measured by its relative strength

About Quantum BioPharma Ltd. (QNTM)

Before we jump into Quantum BioPharma Ltd.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company’s lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. It also develops FSD-PEA, which is in preparation for Phase 2 trial for the treatment of inflammatory diseases, such as mast cell activation syndrome; Lucid-PSYCH to treat major depressive disorder; and unbuzzd, a dietary supplement for the treatment of alcohol misuse. In addition, the company maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd. was founded in 1998 and is based in Toronto, Canada.

Want to learn more about Quantum BioPharma Ltd.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Quantum BioPharma Ltd..

Quantum BioPharma Ltd.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Quantum BioPharma Ltd.’s stock price was $2.890.

Quantum BioPharma Ltd. is up 1.76% from its previous closing price of $2.840.

During the last market session, Quantum BioPharma Ltd.’s stock traded between $2.770 and $2.960. Currently, there are approximately 4.49 million shares outstanding for Quantum BioPharma Ltd..

Quantum BioPharma Ltd.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Quantum BioPharma Ltd. Stock Price History

Quantum BioPharma Ltd.’s (QNTM) price is currently down 20.17% so far this month.

During the month of July, Quantum BioPharma Ltd.’s stock price has reached a high of $3.710 and a low of $2.695.

Over the last year, Quantum BioPharma Ltd. has hit prices as high as $31.914 and as low as $2.070. Year to date, Quantum BioPharma Ltd.’s stock is down 60.41%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Quantum BioPharma Ltd. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 31, 2026, there were analysts who downgraded Quantum BioPharma Ltd.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Quantum BioPharma Ltd.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Quantum BioPharma Ltd.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Quantum BioPharma Ltd. (QNTM) by visiting AAII Stock Evaluator.

Relative Price Strength of Quantum BioPharma Ltd.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 31, 2026, Quantum BioPharma Ltd. has a weighted four-quarter relative price strength of -39.30%, which translates to a Momentum Score of 4 and is considered to be Very Weak.

Want to learn more about how Quantum BioPharma Ltd. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Quantum BioPharma Ltd. Stock Price: Bottom Line

As of July 31, 2026, Quantum BioPharma Ltd.’s stock price is $2.890, which is up 1.76% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Quantum BioPharma Ltd. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.